BridgeBio Pharma Director Douglas Dachille Receives Equity Awards

BridgeBio Pharma, Inc. (BBIO) director Douglas A. Dachille received equity awards on June 22, 2026, as reported in this Form 4 filing. Dachille was granted 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, contingent on his continued board service. Each RSU represents a contingent right to receive one share of common stock. Additionally, he received a stock option for 5,277 shares with an exercise price of $68.92 per share, also vesting on June 22, 2027. The filing also discloses that 20,000 common shares are held indirectly by The Dachille 2012-1 Family Trust for the benefit of Dachille's children, though he disclaims beneficial ownership for Section 16 purposes. The document includes a power of attorney appointing company representatives to file SEC forms on Dachille's behalf.